Stock CGEM CULLINAN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Cullinan Therapeutics, Inc.

Equities

CGEM

US2300311063

Market Closed - Nasdaq
Other stock markets
 01:30:00 29/06/2024 am IST 		5-day change 1st Jan Change
17.44 USD +2.05% Intraday chart for Cullinan Therapeutics, Inc. +0.06% +71.15%
02/06 Transcript : Cullinan Therapeutics, Inc. - Special Call
01/06 Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of Zipalertinib CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
AQ
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
GL
Cullinan Therapeutics : Full Pipeline Overview
PU
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
GL
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
GL
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
GL
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
GL
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
AQ
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
GL
Cullinan Oncology : Therapeutics Corporate Update
PU
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
GL
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
AQ
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
GL
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
GL
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
GL
Cullinan Oncology to Participate in Upcoming Investor Conferences
GL
Cullinan Oncology to Participate in Upcoming Investor Conferences
AQ
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GL
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
GL
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CGEM Stock
  4. News Cullinan Therapeutics, Inc.
  5. Press Releases